Tarsons Products Limited announced the outcome of its Board Meeting held on February 06, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. In a significant strategic move, the company approved an equity infusion of EUR 3 Million (approximately ₹27 crore) into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd. This capital will be used to meet operational and financial expenses, including repayment of existing loans. The infusion is planned in quarterly tranches on or before March 31, 2027. Furthermore, the Board approved the appointment of Mr. Vinesh Mohan Kriplani as an Additional Director (Non-Executive Independent Director) for a term of five years, effective February 06, 2026, subject to shareholder approval. Mr. Kriplani brings over 29 years of experience in corporate and international taxation, M&A, and restructuring. Concurrently, Mr. Girish Paman Vanvari resigned as an Independent Director, effective February 06, 2026, due to personal commitments. He also ceased to be the chairperson of the Audit Committee & Risk Management Committee and a member of the Nomination and Remuneration Committee. Following these changes, the Board reconstituted the Audit Committee, Nomination and Remuneration Committee, and Risk Management Committee.
